Connor, Clark & Lunn Investment Management (CC&L)
TBIO

Connor, Clark & Lunn Investment Management (CC&L)’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-99,155
Closed -$2.73M – 1273
2021
Q2 		$2.73M Buy
99,155
+33,866
+52% +$666K 0.01% 481
2021
Q1 		$1.08M Buy
65,289
+19,218
+42% +$438K 0.01% 678
2020
Q4 		$849K Buy
+46,071
New +$825K 0.01% 657

Connor, Clark & Lunn Investment Management (CC&L)'s TBIO Position: Q3 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 99,155 shares — an estimated $2.73M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TBIO in Q4 2020 and held it in 3 quarters. The position peaked at $2.73M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 99,155 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $2.73M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Translate Bio, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Translate Bio, Inc. Common Stock position peaked at $2.73M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2021, filed 12 Nov 2021.